The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Ischemic Heart Disease (IHD) Drugs Market Expected To Change Between 2026 And 2030?
The ischemic heart disease (ihd) drugs market size has seen steady expansion in recent years. This market is anticipated to expand from $6.65 billion in 2025 to $6.9 billion by 2026, registering a compound annual growth rate (CAGR) of 3.7%. Historically, this expansion can be linked to several factors: a rising prevalence of coronary artery disease, an increasing geriatric population, growing awareness of cardiovascular health, a high incidence of lifestyle-related risk factors, and the widespread availability of generic drugs.
The market for ischemic heart disease (ihd) drugs is projected to experience consistent expansion over the upcoming years. This market is forecast to reach a size of $7.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. Contributing factors to this anticipated growth include progress in precision medicine, the incorporation of digital health solutions, increased acceptance of combination therapy, the creation of innovative drug delivery systems, and the spread of telehealth and remote monitoring. Key trends expected during this forecast timeframe encompass personalized cardiac therapy, combination drug formulations, cardiac care facilitated by telemedicine, the prediction and monitoring of cardiovascular risk, and minimally invasive drug delivery methods.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Which Economic Or Industry Drivers Are Impacting The Ischemic Heart Disease (IHD) Drugs Market?
The rising occurrence of heart failure is projected to stimulate the expansion of the ischemic heart disease (IHD) drug market in the future. Heart failure is defined as a persistent ailment where the heart’s muscle struggles to adequately pump blood, thus failing to supply the body with sufficient blood and oxygen. This insufficiency can result in symptoms such as tiredness, breathlessness, and challenges with daily tasks. Medications for ischemic heart disease (IHD) are crucial in managing heart failure. These drugs can help prevent heart failure by mitigating the risk factors and symptoms associated with ischemic heart disease. Specifically, Ischemic Heart Disease (IHD) drugs work by suppressing the heart’s pacemaker activity, offering benefits to heart failure patients who have reduced ejection fractions and elevated resting heart rates, particularly after they have tolerated a beta-blocker. For example, data from September 2023, provided by the US-based Heart Failure Society of America, indicates that 6.7 million Americans aged over 20 currently suffer from heart failure (HF), a figure anticipated to climb to 8.5 million Americans by 2030. Consequently, the rising occurrence of heart failure is propelling the expansion of the ischemic heart disease (IHD) drug market.
How Is The Ischemic Heart Disease (IHD) Drugs Market Structured Across Different Segments?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Which Trends Are Shaping The Future Of The Ischemic Heart Disease (IHD) Drugs Market?
Major companies engaged in the ischemic heart disease (IHD) drugs market are prioritizing the attainment of advanced regulatory approvals and the expansion of drug indications. This strategy aims to strengthen therapeutic options and secure a larger market share. For example, in June 2023, the US-based biopharmaceutical company Bristol Myers Squibb announced the European Commission’s approval of Camzyos (mavacamten). This drug is recognized as the first allosteric, selective cardiac myosin inhibitor for managing symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). In the same year within the U.S., the FDA endorsed a supplemental new drug application, relying on Phase 3 VALOR HCM data that revealed a significant reduction in the eligibility for septal reduction therapy among patients who were treated. Thus, the increasing regulatory momentum and label expansions for myosin inhibitors are acting as key drivers for growth in the IHD drug market.
Which Major Players Dominate The Ischemic Heart Disease (IHD) Drugs Market?
Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC
Read the full ischemic heart disease (ihd) drugs market report here:
What Are The Top-Performing Regions Within The Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Ischemic Heart Disease (IHD) Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2026, By The Business Research Company
Ischemic Heart Disease Ihd Drugs Market Report 2026
Acute Ischemic Stroke Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model